MRFF National Critical Research Infrastructure Initiative - 2024 Clinical Trial Enabling Infrastructure

Overview

The 2024 Clinical Trial Enabling Infrastructure grant opportunity focuses on promoting development and implementation of ‘adaptive platform’ and ‘registry based’ clinical trials which are thought to offer more efficient evaluation of potential medical therapies over conventional trial designs. This grant opportunity will provide grants of financial assistance across three streams, to support Australian medical research and medical innovation projects that: Stream 1: address an area of unmet medical need by promoting the development and implementation of adaptive platform trials. Funding under Stream 1 is available as follows: Topic A (Incubator): conducting inception projects that build evidence and capability to demonstrate the feasibility of establishing a national adaptive platform trial that would allow for rapid assessment of pharmacological and/or non-pharmacological interventions in an area of unmet need (up to $300,000). Topic B (Targeted Call for Research): establishing a new national adaptive platform trial that addresses an area of unmet need, including set up of central infrastructure and conduct of initial launch domains (up to $5,000,000). Topic C (Targeted Call for Research): expanding an existing adaptive platform trial by adding new domains that address an area of unmet need (up to $3,000,000). Stream 2 (Targeted Call for Research): conduct a registry-based randomised controlled trial in an area of unmet medical need by embedding a registry-based randomised controlled trial into a pre-existing clinical registry (up to $1,500,000). Stream 3 (Targeted Call for Research): establish a new clinical trial practice network or extend an existing clinical trial practice network to consolidate and strengthen sector capability in clinical trials and collaboration, with the aim of embedding evidence-based care in the health system and improving health outcomes, in an area of unmet medical need (up to $7,000,000).